This is the official site for O.S.C.T. - Happy St. Patrick's Day

Ontario Society of Cardiology Technologists (O.S.C.T.)
Ontario Society of Cardiology Technologists (O.S.C.T.)
  • Home
  • About O.S.C.T.
  • A.G.M.
  • News
  • Information
  • Resources
  • C.E.U.'s
  • Event Information
  • Contact Us
  • More
    • Home
    • About O.S.C.T.
    • A.G.M.
    • News
    • Information
    • Resources
    • C.E.U.'s
    • Event Information
    • Contact Us

  • Home
  • About O.S.C.T.
  • A.G.M.
  • News
  • Information
  • Resources
  • C.E.U.'s
  • Event Information
  • Contact Us

New Links for Members

Here are some brand new links for C.E.U. opportunities.

You asked, We brought 'em

How to Upload Your C.E.U.'s

How to upload your CEUs to your profile: A step by step walkthrough. * Please note * Images may appear slightly different depending upon your device, and or web browser.

Why CEU's

Support where you need it

A self-governing body, the CSCT admits and revokes membership in the Society and encourages all members to maintain professional standards by participating in a Continuing Education Units (CEU) system. With technology advancing so rapidly, the CSCT is working to upgrade and maintain national professional standards in the field of Cardiac testing. Today we have over 2,000 Associate and Registered members in Canada.

CEU Information

The Ontario Society of Cardiology Technologists. A place with a heart.

PLEASE NOTE:

 Starting January 2023 please follow this link for important Continuing Education Unit information by pasting  https://www.csct.ca/New-CEU-Process in your bar of your browser or click the link below.

New C.S.C.T. C.E.U. Process

Free CEU Links

CEU Guidelines

Detail your services 

 Continuing Education Units (CEUs) are intended to broaden the knowledge base of the professional technologist. The CSCT and OSCT’s goal is to maintain a high standard of excellence and quality within our membership. The following CEU guidelines will help guide members in their endeavor to obtain CEUs. CEUs should be obtained from current sources and add to the basic knowledge members received during their schooling and subsequent employment, therefore CEUs must be above entry level to practice or “basic level” to earn units. Subject matter that a member is reasonably expected to have learned prior to writing the CSCT exam cannot be accepted as a continuing education unit i.e. Cardiac physiology, normal heart rhythms, etc. Below are some guidelines to support members in their endeavor to obtain CEUs. Advanced CEUs are routinely provided through both the OSCT and CSCT websites. 

CEU Standards Guidelines

1. Only CEUs accumulated and submitted during the current triennium will be accepted.

2. Documentation or proof of attendance must accompany all CEU submissions. Members are responsible for keeping originals of all documentation in case of a discrepancy. CEU coordinators may or may not keep copies of CEU’s obtained.

3. Every submission must be Cardiology related.

4. Job requirements may not necessarily meet the criteria for CEU’s. i.e. code blue review, hardware/software instructions

5. Formal classes must be from an accredited program and must fall under the NOCP guidelines.

6. Preceptors must be for a Cardiology Technology program or CLXT/MLA and from an accredited program recognized by the CSCT

7. Members will receive 1 CEU for every 30-minute video cited, or 2 CEU’s if there is a summary written about it.

8. Members must submit the learning objective and instructor for any lectures or in-services. If it falls under “entry level to practice” according to the NOCP guidelines, members will only receive 2 CEU’s per triennium for these activities.

9. CEU’s for teaching will not be granted if you are being paid as an instructor from an educational institution. They must be accumulated for teaching during working hours or volunteering after hours.  

EP Lab Efficiencies

EP Lab Efficiencies Description:

To ensure optimal care and outcomes for patients with atrial fibrillation, hospitals and electrophysiologists will need to take a systems-based approach to EP lab efficiency, focused on standardizing processes while reducing waste and errors. Fortunately, the same processes used to achieve improvement in patient safety and outcomes, and even facilitate research, can simultaneously result in improved capacity.

On May 27-28, 2021, a group of Heart Rhythm Society members and staff visited Dr. Jose Osorio and his EP team at Grandview Medical Center in Birmingham, Alabama. The purpose of the visit was to learn about the improvement processes put in place to enhance both quality and efficiency. HRS members in attendance included electrophysiologists at different stages of their own quality improvement journeys. This video series captures the group's observations and the many lessons learned during the visit. The group describes how the transformational approach to quality improvement that Dr. Osorio and his team have implemented successfully at their program in Birmingham can be accomplished in EP labs everywhere.

Learners will be able to view the full series of 7 videos or select only the topics and sections of interest. Transcripts for each video are also provided.
The 7 videos cover the following areas of focus:
(1) why EP labs should focus on efficiency;
(2) an explanation of the Grandview model;
(3) how to implement principles of quality improvement in an EP lab;
(4) the importance of team member involvement;
(5) the relationship between electrophysiology and anesthesiology departments;
(6) engagement with the patient and caregiver; and
(7) reproducing the model in your own institution. 


Learning Objectives Upon completion of this activity, participant should be able to:

1. Describe how to standardize processes to achieve better outcomes.
2. Create a cohesive team environment, improve staff morale, and reduce turnover by involving staff in setting expectations and by creating predictable work schedules.
3. Develop a standard protocol for the patient experience.
4. Construct processes, identify benchmarks, set expectations, and measure improvements.
5. Describe how to reduce turnover time.
6. Explain how to work with the anesthesiology department to schedule patients and implement protocols that improve patient care.
7. Determine a plan for implementing efficiency in the EP lab.

Target Audience

This activity is intended for all who study and treat heart rhythm disorders. 

Web Link

TAVR in Patients with Bicuspid Anatomy: Considerations in Patient Selection

Duration: 1 hour

CEU Value: 1

CSCT CEU STANDARDS SECTION: 2F

Link:     TAVR in Patients with Bicuspid Anatomy | myCME   

Expires: November 16, 2022

Description:

 

Program Description

Although patients with a bicuspid aortic valve (BAV) currently account for nearly half of aortic valve replacement (AVR) procedures, they were excluded from the pivotal clinical trials leading to US Food and Drug Administration approval of transcatheter AVR (TAVR). Nevertheless, there is a robust body of real-world data documenting good outcomes with TAVR in this population. In this Expert Perspectives webinar, three noted cardiologists review how the distinct morphologic features of bicuspid valves may impact TAVR outcomes and provide insights on the factors that determine which patients with bicuspid anatomy are candidates for TAVR and which may be better served by a traditional surgical approach.

TAVR in Bicuspid Valves: An Update from Dr. Tsuyoshi Kaneko from the 2022 Annual Meeting of the Society of Thoracic Surgeons

Duration: 30 minutes

CEU Value: 1

Expires: April 15, 2023

CSCT CEU STANDARDS SECTION: 2F

Link: TAVR in Bicuspid Valves: Update from STS 2022 | myCME 

Description:

 

Program Description

 Dr. Tsuyoshi Kaneko lends an expert perspective on the rapidly growing evidence base on the role of transcatheter aortic valve replacement (TAVR) in patients with bicuspid valve anatomy, including the most recent data presented at the 2022 annual meeting of the Society of Thoracic Surgeons (STS). While outcomes can rival those seen with traditional surgical valve replacement, Dr. Kaneko notes important caveats regarding proper patient selection that underscore the need for assessment by a heart valve team when deciding between the two approaches.

Strategies for Individualizing PAH Treatment to Ensure Optimal Patient Outcomes

Duration: 1 hour

CEU Value: 1

Expires: June 9, 2023

CSCT CEU STANDARDS SECTION: 2F

Link:  Individual PAH Treatment to Ensure Optimal Outcomes | myCME  

Description:

 

Program Description

In this activity, leading experts discuss appropriate diagnostic measures that differentiate pulmonary arterial hypertension (PAH) from other disorders. Additionally, these experts will provide strategies on individualizing treatment for patients with PAH based on the latest practice-altering clinical trial data in the field of PAH.

Novel Agents Targeting the Source of HCM Disease

Duration: 30 minutes

CEU Value: 0.5

Expires: May 10, 2023

CSCT CEU STANDARDS SECTION: 2F

Link:   Novel Agents Targeting the Source of HCM Disease | myCME   

Description:

 

Program Description

Hypertrophic cardiomyopathy (HCM) is prevalent around the world, with a conservatively estimated 20 million individuals affected. Even in developed countries, current management of HCM is suboptimal. Much has been learned over the past 2 decades about the pathophysiology of HCM and new therapies such as mavacamten, CK-274, IMB-101, and CT-G20 are currently being developed and tested in clinical trials addressing the underlying pathophysiology of HCM. Although these new agents are in late stages of development, clinicians are often not fully up to date on this progress and the potential opportunity to improve care for patients.


Please join Drs. Maron and Rakowski in this final installment of a CMEO Snack series on HCM as they discuss methods to assess study results of emerging HCM disease-specific treatments targeting cardiac myosin in order to optimize outcomes for patients.

HCM Around the Globe: Not an Isolated Issue

Duration: 30 minutes

CEU Value: 0.5

Expires: May 10, 2023

CSCT CEU STANDARDS SECTION: 2F

Link:    HCM Around the Globe: Not an Isolated Issue | myCME    

Description:

 

Program Description

Hypertrophic cardiomyopathy (HCM) is an under-recognized, common, and treatable genetic disease occurring worldwide. HCM is a myocardial disorder most often caused by mutations in one of several sarcomere genes that encode components of the contractile apparatus of the heart. It is characterized by ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. Adding to the burden of disease, HCM can present with a variety of symptoms mimicking other conditions and may go undiagnosed for many years and it is estimated that approximately one in 500 individuals in the United States may have clinically unrecognized, undiagnosed HCM, with an overall prevalence estimated at 750,000.

Please join Dr. Maron and Dr. Torres in this first installment of a CMEO Snack series as they discuss strategies for optimal screening of HCM in an effort to increase recognition and diagnosis of this too often misdiagnosed disease.

Racial Disparities in Cardiac Arrhythmia Care: A Call to Action

Duration: 45 minutes

CEU Value: 1

Expires: March 3, 2023

CSCT CEU STANDARDS SECTION: 2F

Link:     Racial Disparities in Cardiac Arrhythmia Care | myCME    

Description:

 

Program Description

Statement of Need

Racial disparitiesin potentially life-saving interventional cardiology care exist and persist even with otherwise equal access to care. Untreated or undertreated cardiac arrhythmias, such as atrial fibrillation (AF) can have serious consequences, including heart failure (HF)and stroke. Action steps for clinicians to help mitigate health disparities in cardiac arrythmia care include increased awareness of disparities and improved adherence to guidelines for HF management.


In this CME Outfitters BriefCase, expert faculty will present two to three patient cases that will showcase how clinicians can integrate best practices to mitigate disparities in the management of cardiac rhythm disorders across race, ethnicity, and gender.

Appropriate Use of SGLT2s and GLP-1RAs with Insulin to Reduce CVD Risk in Patients with Diabetes

Duration: 1 hour

CEU Value: 1 

Expires: December 27, 2022

CSCT CEU STANDARDS SECTION: 2F

Link:  Treatments to Reduce CVD Risk in Patients with Diabetes | myCME 

Description:

 

Program Description

Patients with type 2 diabetes mellitus are prone to hypertension, dyslipidemia, and coronary artery disease leading to a high risk of myocardial infarction, heart failure, and stroke in these patients. Adequate control of diabetes mellitus is essential to mitigate this risk, and underlying co-morbidities such as hypertension and dyslipidemia must be well controlled to minimize cardiovascular risks in patients with type 2 diabetes. However, there is no set algorithm to achieve this target, and a patient-centered approach, evaluating their specific risk factors, is warranted. Choice of medical therapy should be individualized to obtain the best possible outcome for each patient. Initial treatment rests on educating the patient about glycemic control and appropriate lifestyle changes such as tobacco cessation, increasing exercise, and reducing body weight. However, patients with established cardiovascular disease or those at high risk of this disease warrant special consideration to prevent poor outcomes. This activity describes the evaluation and management of cardiovascular risks in patients with type 2 diabetes mellitus and emphasizes using sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor antagonist (GLP-1RA) drugs in conjunction with insulin to mitigate this risk. It also highlights the role of the interprofessional team in improving care for patients with these conditions.

Cardiac Amyloidosis: Accelerating Diagnosis and Treatment

Duration: 1 hour

CEU Value: 2 (All Components must be completed)

Expires: December 27, 2022

CSCT CEU STANDARDS SECTION: 2F

Link:   Cardiac Amyloidosis: Accelerating Diagnosis and Treatment 

Description:

 

Program Description


Podcast

Red Flags/Clinical Clues for Considering Cardiac Amyloidosis


Patient Case Quiz

Diagnosis of LVH

When to Suspect Cardiac Amyloidosis


Slide Lecture

Red Flags and Clinical Clues - When to Suspect Cardiac Amyloidosis

Heart Failure with Preserved Ejection Fraction as an Exercise Deficiency Syndrome: JACC Focus Seminar

Duration: 1 hour

CEU Value: 1 (All Components must be completed)

Expires: December 27, 2022

CSCT CEU STANDARDS SECTION: 2F

Link:    Heart Failure With Preserved Ejection Fraction as an Exercise Deficiency Syndrome: JACC Focus Seminar 2/4 | Journal of the American College of Cardiology 

 

Program Description


Across differing spectrums of cardiac function and cardiac pathologies, there are strong associations between measures of cardiorespiratory fitness and burden of symptoms, quality of life, and prognosis. In this part 2 of a 4-part series, we contend that there is a strong association among physical activity, cardiorespiratory fitness, and cardiac function. We argue that a chronic lack of exercise is a major risk factor for heart failure with preserved ejection fraction in some patients. In support of this hypothesis, increasing physical activity is associated with greater cardiac mass, greater stroke volumes, greater cardiac output and peak oxygen consumption, and fewer clinical events. Conversely, physical inactivity results in cardiac atrophy, reduced output, reduced chamber size, and decreased ability to augment cardiac performance with exercise. Moreover, physical inactivity is a strong predictor of heart failure risk and death. In sum, exercise deficiency should be considered part of the broad heart failure with preserved ejection fraction phenotype.

Transvenous Right Greater Splanchnic Nerve Ablation in Heart Failure and Preserved Ejection Fraction: First-in-Human Study

Duration: 1 hour

CEU Value: 1 (All Components must be completed)

Expires: December 27, 2022

CSCT CEU STANDARDS SECTION: 2F

Link:    Transvenous Right Greater Splanchnic Nerve Ablation in Heart Failure and Preserved Ejection Fraction: First-in-Human Study | JACC: Heart Failure  

 

Program Description


Background

Ablation of the right-sided greater splanchnic nerve (GSN) can reduce excessive splanchnic vasoconstriction, potentially improving the handling of volume shifts in patients with heart failure with preserved ejection fraction (HFpEF).

Objectives

The purpose of this study was to assess a novel catheter procedure of right sided GSN ablation to treat HFpEF: splanchnic ablation for volume management.

CEU Opportunities

Cardiocases Web Site

Pacing & Defibrillation

Unique and guided training

New EP cases

Train yourself using our online electrophysiology system.

Take this course and earn 10 CEU'S for the full suite!

Copyright © 2023 Ontario Society of Cardiology Technologists (O.S.C.T.) - All Rights Reserved.

  • Home
  • About O.S.C.T.
  • A.G.M.
  • News
  • Information
  • Resources
  • C.E.U.'s
  • Event Information
  • Contact Us